Oral Chinese Patent Mediciens for Lung Cancer：A Scoping Review of Clinical Evidence
10.13422/j.cnki.syfjx.20220895
- VernacularTitle:口服中成药治疗肺癌临床研究证据的概况性综述
- Author:
Juan WANG
1
;
Xu HAN
1
;
Miao JIANG
1
;
Hong-tao GUO
2
;
Hao GU
1
;
Xing LIAO
1
Author Information
1. Institute of Basic Research in Clinical Medicine， China Academy of Chinese Medical Sciences， Beijing 100700，China
2. The First Affiliated Hospital of Henan University of Chinese Medicine，Zhengzhou 450000，China
- Publication Type:Journal Article
- Keywords:
oral Chinese patent medicine;
lung cancer;
clinical research;
scoping review
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2022;28(8):204-213
- CountryChina
- Language:Chinese
-
Abstract:
This scoping review aimed to summarize the application information and clinical studies of oral Chinese patent medicines. The oral Chinese patent medicines in treating lung cancer were screened out by searching pf the drug directory， related guidelines， and medical information websites. The data including functions， application， ingredients， and prices of these medicines were collected. Six public databases were searched with the time interval of establishment to August 22， 2021 for collection of the clinical studies of oral Chinese patent medicines in the treatment of lung cancer. The expert consensuses， systematic reviews， randomized controlled trials， non-randomized controlled trials， and non-controlled trials were selected for analysis. A total of 104 oral Chinese patent medicines were screened out， including 31 capsules， 16 granules， 20 oral liquids， 17 tablets， 17 pills， and 3 ointments， in which altogether 198 herbal medicines were involved. The single-dose prices of 2， 36， and 66 medicines were > CNY 100， CNY 10-100， and < CNY 10， respectively. There were 410 clinical studies associated with 48 oral Chinese patent medicines， which were published from 1986 to 2021. These publications included 1 expert consensus， 21 systematic reviews， 277 randomized controlled trials， 87 non-randomized controlled trials， and 24 non-controlled trials. In the clinical studies， the Chinese patent medicines were usually applied in combination with radiotherapy and chemotherapy. The evaluation of primary outcomes focused on 9 indicators including clinical efficacy， quality of life， and incidence of side effects. In conclusion， the oral Chinese patent medicines demonstrated significant advantages in the treatment of lung cancer， and the relevant clinical trials were increasing year by year， with multiple outcome indicators being evaluated. More comprehensive and standardized clinical studies need to be designed for oral Chinese patent medicines in treating lung cancer in the future.
